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A high rate of sleep apnea syndrome (SAS) complicated by atrial ﬁbrillation (AF) has been
reported. We reviewed the frequency of SAS complications in AF patients, and reported on
the patients for whom SAS was considered to be a cause of the AF. We studied 28 patients
with AF who were able to receive a sleep apnea examination. All patients had oxygen
saturation measured by an ambulatory percutaneus monitor (PULSOX) during sleep. A sleep
apnea examination was performed by polysomnograph (Morpheus) in 19 of the patients.
There were 18 patients (64%) with moderate to severe SAS whose apnea hypoxia index (AHI)
or 3% oxygen disaturation index was more than 20. In this study, AF was stopped by treating
SAS with continuous positive airway pressure (CPAP) or noninvasive positive pressure
ventilation (NPPV) in 2 cases. Our study shows a high rate of SAS complications with AF,
which is in accord with previous studies. We experienced cases in which AF was stopped by
treating SAS with CPAP or NPPV, suggesting it is a cause of AF.
(J Arrhythmia 2007; 23: 152–156)
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Introduction
Many cardiovascular diseases are complicated by
sleep apnea syndrome (SAS), which is considered to
be an aggravating factor. About 60 percent of heart
failure patients have SAS,1–3) and subjective and
objective symptoms of heart failure have been
improved by treating SAS with oxygen inhalation
therapies.4–7) In addition, SAS has attracted attention
as a causative disease in hypertensive patients.8–13) It
has been reported that the rate of SAS complications
with atrial ﬁbrillation(AF) is high.14) We reviewed
the frequency of SAS complications in AF patients
at our hospital, and report cases in whom SAS is
considered to be a cause of AF.
Case Report
We studied 28 patients with chronic atrial ﬁbril-
lation (Caf) or paroxysmal atrial ﬁbrillation (Paf)
who were able to receive a sleep apnea examination
in Kouseiren Takaoka Hospital from October, 2004
to January, 2006. Caf is a condition in which AF
continues for more than 1 year, and in Paf AF lasts
for 24 hours or less. When their medical therapy
started, the AF was Caf in 12 patients and Paf in 16
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Case Report
patients. Four Paf patients had their deﬁbrillation
treated successfully with antiarrhythmic drugs
(Table 1). The mean age was 67 11. There were
23 men and 5 women.
All patients had their oxygen saturation measured
by an ambulatory percutaneus monitor (PULSOX,
TEIJIN PHARMA Ltd.) during sleep. When epi-
sodes indicating a 3% oxygen disaturation index
(3%ODI) more than 10 times every hour were
obtained under close observation during hospital-
ization, which corresponds to an oxygen saturation
dose degradation of more than 3%, a sleep apnea
examination was performed using Morpheus (TEI-
JIN PHAMA Ltd.). This device is able to measure
6 parameters: nasal air ﬂow, chest and abdominal
movements, pulse rate, percutaneus oxygen satura-
tion, and physical position. Using Morpheus, we can
distinguish the type of SAS, and measured the apnea
hypoxia index (AHI), which is the number of apnea
and hypoxia events per hour. Apnea is deﬁned as
nasal air-ﬂow arrest for more than 10 seconds, and
hypoxia as a reduced nasal air ﬂow with an oxygen
disaturation of more than 3%. Nineteen patients were
evaluated using Morpheus and 9 patients using only
PULSOX.
Table 1 shows patient characteristics and outcome
for all cases. Among the 9 patients we evaluated only
using PLUSOX, there were 7 patients whose 3%ODI
was 10 or less, 2 patients above 20, and no patients
between 11 and 19. Among the 19 patients evaluated
using Morpheus, there were 3 patients whose AHI
was below 10, 16 patients more than 20, and no
Table 1 Clinical characteristics and results for all cases.
No initial age sex AHI ODI EF disease Paf or Af Afduration antiarrhythmic drugs SAS treatment
1 O.T. 75 F 29 79 HT Caf 16y none
2 O.M. 58 M 2 65 MSR Paf bepridil
3 K.J. 74 F 5 76 PE Paf bepridil
4 T.K. 77 M 40 57 HT Caf 1y< bepridil NPPV
5 T.O. 79 M 53 72 SSS, HT, HL Paf none CPAP
6 I.K. 60 M 28 57 MR Caf 5y< none HOT
7 M.Y. 61 M 42 63 HT Paf bepridil NPPV
8 S.A. 61 M 47 68 HT, MR Caf->SR 3y< bepridil
9 T.H. 61 F 3 63 SSS Caf bepridil
10 S.H. 53 M 29 67 none Paf ﬂecainide
11 K.T. 80 M 18 73 HT, HL Paf pilsicainide
12 M.M. 80 F 33 66 SSS Paf bepridil+pirmenol HOT
13 H.K. 62 M 33 34 DCM, HL Paf bepridil
14 M.E. 82 M 40 56 HT, HL, CRF Paf bepridil
15 S.S. 75 M 20 68 DM Paf bepridil
16 M.H. 85 M 36 45 HT, DM, CRF Caf 3y< none
17 H.M. 70 M 38 68 none Paf bepridil+pilsicainide
18 R.T. 67 F 47 68 DM, HT Paf none CPAP
19 T.S. 83 M 29 56 HL Caf 2y< none
20 Y.Y 70 M 9 72 HT Caf->SR 1y bepridil+ﬂecainide
21 Y.T 57 M 1 64 HT, HL Caf->SR 3y< bepridil+ﬂecainide
22 Y.K. 73 M 8 50 SSS, DM Paf bepridil+pilsicainide
23 M.S. 58 M 7 74 HT Caf->SR 1y bepridil
24 N.K. 52 M 22 69 none Paf bepridil
25 T.M. 59 M 10 60 SSS, HT Paf bepridil+ﬂecainide
26 M.K. 59 M 28 64 none Caf 6y none
27 K.M. 46 M 1 74 DM Paf bepridil+pilsicainide
28 Y.S. 58 M 8 70 HT Caf 1y bepridil+ﬂecainide
AHI, apnea hypoxia index; ODI, oxygen disaturation index; EF, ejection fraction; HT, hypertension; MSR, mitral stenosis and
regurgitation; PE, pulmonary embolism; SSS, sick sinus syndrome; HL, hyperlipidemia; MR, mitral regurgitation; DCM,
dilated cardiomyopathy; CRF, chronic renal failure; DM, diabetes mellitus; SR, sinus rhythm; NPPV, noninvasive positive
pressure ventilation; CPAP, continuous positive airway pressure; HOT, home oxygen therapy
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patients between 10 and 19. There were 18 patients
(64%) with moderate to severe SAS, in whom AHI
or 3%ODI was more than 20.
In this study, we treated SAS in 6 patients, and 2
had atrial ﬁbrillation treated successfully with SAS.
Case 1 was No. 18, a 67 year-old woman with Paf,
who was observed to have seizures only during
sleep, even when napping. Her episodes of Paf
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Figure 1 Polysomnography in case 1.
O, obstructive apnea; H, hypoxia; S, snore; D, disaturation.
Although nasal air ﬂow stops, chest and abdominal movements are observed. This is obstructive apnea.
(A) 
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Figure 2
(A) Heart rate trend graph for case 1 during sleep.
PACs often occur just before heart rate increase. This phase corresponds to the time hyperpnea began.
(B) Heart rate trend recorded by 24-hour ambulatory Holter monitor for case 1.
During sleep PACs occurred frequently and induced AF.
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occurred daily. Her AHI was 47, and the type of SAS
was obstructive (Figure 1). In this case, premature
atrial contractions (PACs) were observed in hyper-
ventilation, which followed apnea (Figure 2A), when
we reviewed the onset of Paf at the time of sleep
apnea, and shifted to Paf (Figure 2B). AHI was
air flow
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Figure 3 Polysomnography for case 2.
C, central type apnea; M, mixed type apnea.
Nasal air ﬂow and chest and abdominal movements stop synchronously. This is central apnea.
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Figure 4 Electrocardiograms for
case 2.
A, Before treatment of SAS; B, After
treatment of SAS.
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improved to single ﬁgures by continuous positive
airway pressure (CPAP) treatment, and she had no
Paf after 1 year of follow-up treatment.
Case 2 was No. 4, a 77 year-old man with Caf.
Figure 4A shows his ECG. His SAS was central and
mixed type, and his AHI was 40 (Figure 3). His AF
stopped after starting therapy for SAS with non-
invasive positive pressure ventilation (NPPV) on the
second day (Figure 4). He had maintained sinus
rhythm for more than a half year. Hence, when he
could not undergo NPPV because of a cold, Af
recurred. After resuming NPPV, sinus rhythm
returned.
Discussion
In our study, the rate of SAS complication to AF
was 64%, which is considerably higher than that in a
previous report.14)
We experienced 2 cases whose AF was controlled
by treating SAS. In case 1, SAS was regarded as a
true cause of AF. In this case, premature atrial
contractions (PACs) were observed in hyperventila-
tion, which followed apnea. In a previous study of
premature ventricular contraction (PVC) in heart
failure patients with Cheyne-Stokes breathing,15,16)
there were signiﬁcantly large numbers of PVCs in
hyperpnea phases compared to apnea phases. It has
been conﬁrmed that sympathetic activity rises in
hyperpnea phases following apnea,17) and elicitation
of rising PACs due to sympathetic activity is thought
to be one of the causes of Paf in case 1. In addition,
we cannot continuously measure blood carbon
dioxide pressure and pH, but alternating these
parameters under SAS might contribute to Paf.
When treating AF with SAS, we experienced
successful prevention or termination of AF with
CPAP or NPPV, which suﬃciently relieved cardiac
load, but did not experience a case terminated only
by oxygenation.
Conclusions
Our study showed as high a rate of SAS
complication with AF as in previous studies. We
experienced cases in which AF was stopped by SAS
treatment, such as CPAP or NPPV, suggesting it
could be considered as being the cause of AF.
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